Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $10.42 to $11.12
• 50-Day Range: $8.81 to $11.25
• 52-Week Range: $6.38 to $17.30
• Volume: 993,392 shs
• Average Volume: 986,045 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.33
• Consensus Rating: Buy

Avadel Pharmaceuticals Stock Analysis - MarketRank™

Avadel Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 458th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Avadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avadel Pharmaceuticals is -41.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avadel Pharmaceuticals is -41.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avadel Pharmaceuticals has a P/B Ratio of 14.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.72% of the outstanding shares of Avadel Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.

Change versus previous month

Short interest in Avadel Pharmaceuticals has recently decreased by 2.61%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avadel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Avadel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.72% of the outstanding shares of Avadel Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.

Change versus previous month

Short interest in Avadel Pharmaceuticals has recently decreased by 2.61%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.07

News Sentiment

Avadel Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Avadel Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for AVDL on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.20% of the stock of Avadel Pharmaceuticals is held by insiders.

Percentage Held by Institutions

69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVDL Stock Analysis - Frequently Asked Questions

How have AVDL shares performed this year?

Avadel Pharmaceuticals' stock was trading at $10.51 at the beginning of 2025. Since then, AVDL stock has increased by 5.4% and is now trading at $11.08.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) released its earnings results on Wednesday, May, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company's revenue for the quarter was up 93.2% on a year-over-year basis.
Read the conference call transcript.

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' top institutional investors include Wealth Effects LLC (2.43%), Investors Asset Management of Georgia Inc. GA ADV (0.14%), Y Intercept Hong Kong Ltd (0.10%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.02%). Insiders that own company stock include Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis.
View institutional ownership trends.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVDL
• CIK: 1012477
• Web: www.avadel.com
• Phone: (531) 901-5201
• Fax: 353-1526-1077
• Employees: 70
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Avadel Pharmaceuticals: $18.33
• High Price Target: $30.00
• Low Price Target: $12.00
• Potential Upside/Downside: +65.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.83 million
• Net Margins: -13.58%
• Pretax Margin: -13.72%
• Return on Equity: -36.07%
• Return on Assets: -16.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: $194.45 million
• Price / Sales: 5.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.77 per share
• Price / Book: 14.39

Miscellaneous

• Outstanding Shares: 96,739,000
• Free Float: 91,709,000
• Market Cap: $1.07 billion
• Optionable: Optionable
• Beta: 1.47